Treatment Strategies & Options
Update: 2021-07-09
Description
- Goals of treatment: control inflammation, prevent joint and organ damage, minimize treatment-related adverse events; relieve patient burden
- A wide variety of non-biologic and biologic medications are used for treatment, but are supported with limited evidence
- Canakinumab is the only medication approved by the US Food and Drug Administration for the treatment of patients with adult-onset Still’s disease based, in part, on the results of the phase 3 CONSIDER trial
- There is no standardized approach to patient monitoring, but is closely tied to the goals of treatment
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
